Bruker
Maker of magnetic-resonance, mass-spectrometry, and X-ray instruments for scientific and industrial research.
Something off on this page? Send us feedback.
Profile
Builds precision instruments — magnetic-resonance and mass-spectrometry systems anchored by its timsTOF platform, plus X-ray, nano-surface, and superconducting-magnet tools — for research labs in academia, pharma, and industry. Recent acquisitions extend the business into molecular diagnostics and spatial biology, with most revenue generated outside the United States.
Makes precision scientific instruments for reading matter at the molecular and atomic level — magnetic-resonance systems, mass spectrometers built around the timsTOF platform, X-ray and nano-surface analysis tools, and superconducting magnets.
The business traces to 1960, when a physics professor in Karlsruhe, West Germany, began building nuclear-magnetic-resonance instruments that became its founding line.
Recent acquisitions have pushed the portfolio from instrument sales into molecular diagnostics and spatial biology, aiming instruments and testing at the same post-genomic research customers.
Customers are concentrated in academic, pharmaceutical, and industrial research labs, with most sales outside the United States. Research-funding cycles drive demand, and the founding Laukien family, led by the chairman and chief executive, remains its largest shareholder.
Company facts
Categories
Key statistics
Year to date +18.6% · Average volume (30d) 2.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | Stifel Nicolaus | Target | $45 | $50 | |
| Jun 29, 2026 | Guggenheim | Reiterate | Buy | $58 | $70 |
| Jun 24, 2026 | UBS | Target | $45 | $60 | |
| May 8, 2026 | Stifel Nicolaus | Target | $40 | $45 | |
| May 7, 2026 | UBS | Reiterate | Neutral | $49 | $45 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.38 | $0.49 | +27.3% | $853.6M | $838.5M | −1.8% | −21.79% |
| May 6, 2026Q1 FY26 | $0.23 | $0.31 | +34.8% | $795.6M | $823.4M | +3.5% | +3.38% |
| Feb 12, 2026Q4 FY25 | $0.65 | $0.59 | −9.2% | $962.3M | $977.2M | +1.6% | −2.67% |
| Nov 3, 2025Q3 FY25 | $0.33 | $0.60 | +81.8% | $964.6M | $860.5M | −10.8% | +4.31% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $801.4M | $797.4M | $860.5M | $977.2M | $823.4M | $838.5M | |
| Gross profit | $391.2M | $357.9M | $379.4M | $449.2M | $389.3M | $416.0M | |
| Operating income | $31.8M | $11.9M | $35.0M | $111.8M | $45.0M | −$65.3M | |
| Net income | $17.4M | $7.6M | −$59.6M | $26.0M | $14.4M | −$52.0M | |
| Diluted EPS | $0.11 | $0.05 | −$0.41 | $0.10 | $0.02 | −$0.41 | |
| Gross margin | 48.8% | 44.9% | 44.1% | 46.0% | 47.3% | 49.6% | |
| Operating margin | 4.0% | 1.5% | 4.1% | 11.4% | 5.5% | -7.8% |
Fiscal years (4-quarter sums)FY21 $2.42B · FY22 $2.53B · FY23 $2.96B · FY24 $3.37B · FY25 $3.44B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $184.9M · Total debt $1.92B · Total assets $6.05B · Shareholders' equity $2.40B
Dividends
Raised for 9 straight years — most recently to $0.05 from $0.04 in Feb 2022. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 22, 2026 | Jun 22 | Jul 7 | $0.05 | |
| Mar 23, 2026 | Mar 23 | Apr 7 | $0.05 | |
| Dec 8, 2025 | Dec 8 | Jan 2 | $0.05 | |
| Sep 23, 2025 | Sep 23 | Oct 3 | $0.05 | |
| Jun 16, 2025 | Jun 16 | Jun 27 | $0.05 | |
| Mar 17, 2025 | Mar 17 | Mar 28 | $0.05 | |
| Dec 2, 2024 | Dec 2 | Dec 16 | $0.05 | |
| Aug 30, 2024 | Sep 2 | Sep 16 | $0.05 |
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 152.23M · Float 103.62M · 68.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Frank H. Laukien · director, 10 percent owner, officer: PRESIDENT & CEO | 38.51M | 25.30% | Form 4 | Aug 18, 2026 |
| FMR LLC | 20.24M | 13.29% | 13F | Aug 13, 2026 |
| Orbis Allan Gray Ltd | 17.94M | 11.79% | 13F | Aug 14, 2026 |
| Orbis Investment Management Ltd | 16.85M | 11.10% | 13G | May 15, 2026 |
| BlackRock, Inc. | 11.41M | 7.49% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $57.60 |
| Aug 17, 2026 | Wolfgang Pusch | officer: President BMID Group | −3,473 | $56.90 |
| Jul 15, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $60.25 |
| Jun 15, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $54.76 |
| May 15, 2026 | Mark Munch | officer: EXEC VP&PRES BRUKER NANO INC. | −2,000 | $43.90 |
Peers
- Thermo Fisher Scientific
Two-horse-race rival in proteomics MS; also X-ray and CALID overlap
- Danaher
Multi-front rival via SCIEX mass spec, Leica microscopy, and Cepheid MDx
- Agilent Technologies
CALID and NANO segment rival across LC-MS, GC-MS, and X-ray instruments
- Waters
Direct LC-MS rival, scaling up via pending BD Biosciences/Diagnostics deal
- 10x Genomics
Active spatial-biology rival; $68M patent settlement plus ongoing royalties
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Waters | $414.33 | −0.03% | $31.02B | 103.4 | 26.5 | 6.7 | +113.3% |
| 10x Genomics | $61.54 | −0.01% | $7.81B | — | — | 12.7 | −12.7% |
| Median | 35.9 | 24.1 | 6.0 | +8.1% |